Summary Aim To assess the rate of sustained virological response in naïve hepatitis C virus‐type 5 patients treated by standard interferon or percutaneous endoscopic gastrostomy‐interferon (peg‐interferon) and ribavirin combination for 48 weeks. Patients and methods A total of 87 hepatitis C virus patients were included from 12 centres in France; 28 patients received interferon plus ribavirin and 59 were treated with peg‐interferon plus ribavirin. Results Baseline characteristics were: mean age 58 ± 11 years, sex ratio 1, 66% had metavir fibrosis score ≥F2, 21% were cirrhotics and 53% had pretherapeutic viral load ≥800 000 IU/mL. Sustained virological response was achieved in 64% and 58% of hepatitis C virus‐5 patients treated with interferon and peg‐interferon, respectively (NS). In adherent patients, sustained virological response was obtained in 75% of patients. Sustained virological response in hepatitis C virus‐5 patients (60%) was significantly higher than sustained virological response in hepatitis C virus‐1 patients (37%) (P = 0.0499) and not significantly different from sustained virological response in hepatitis C virus‐2–3 patients (63%) (P = 0.8098). Conclusions Combination therapy is effective in 60% of hepatitis C virus‐5‐infected patients. Sustained virological response seems better in hepatitis C virus‐5 patients than in hepatitis C virus‐1 patients, and is similar to that of hepatitis C virus‐2–3 patients. More studies are needed to determine optimal duration of treatment in hepatitis C virus‐5 patients.
Alimentary Pharmacology & Therapeutics – Wiley
Published: Aug 1, 2006
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera